Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

Published:2013-11-27 Issue:4 Volume:54 Page:405-414
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Hohlfeld J.M.¹,Sharma A.²,van Noord J.A.³,Cornelissen P.J.G.²,Derom E.⁴,Towse L.²,Peterkin V.²,Disse B.²

Affiliation:

1. Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM)HannoverGermany

2. Boehringer Ingelheim Pharma GmbH & Co. KGGermany, and affiliates in The Netherlands and UK

3. Department of Respiratory DiseasesAtrium Medisch CentrumHeerlenThe Netherlands

4. Department of Respiratory DiseasesGhent University HospitalGhentBelgium

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.215

Reference22 articles.

1. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

2. From the Global Strategy for the Diagnosis Management and Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from:http://www.goldcopd.org/. Last accessed April 2011

3. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies;Bateman E;Int J Chron Obstruct Pulmon Dis.,2010

4. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients

5. Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans;Frontiers in Nuclear Medicine;2023-01-18

2. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs;Expert Opinion on Drug Delivery;2021-01-19

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers

;International Journal of Chronic Obstructive Pulmonary Disease;2020-12

4. A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma;Expert Opinion on Drug Metabolism & Toxicology;2020-01-30

5. Choosing the right inhaler for the right patient: Considerations for effective management of patients with chronic obstructive pulmonary disease or asthma;Journal of the American Association of Nurse Practitioners;2020-01